血流储备分数指导的经皮冠状动脉介入治疗与冠状动脉旁路移植术后的结局(FAME 3):多中心、开放标签、随机试验的5年随访
FAME 3试验在多中心比较了FFR指导的PCI(使用当代佐他莫司洗脱支架)与CABG治疗不累及左主干的三支血管病变。5年随访时,死亡、卒中或心肌梗死复合终点在PCI组为16%,CABG组为14%(HR 1.16,95%CI 0.89-1.52;p=0.27),无显著差异。心肌梗死(8% vs 5%;HR 1.57,95%CI 1.04-2.36)和再次血运重建(16% vs 8%;HR 2.02,95%CI 1.46-2.79)在PCI组更高。作者认为这些结果可为医患共同决策提供当代证据。
要点
- 在无心源性休克、无近期ST段抬高型心肌梗死、无严重左心室功能障碍且无既往CABG的≥21岁三支血管病变患者中,FFR指导的PCI与CABG的5年死亡、卒中或心肌梗死复合终点无显著差异(16% vs 14%;HR 1.16,95%CI 0.89-1.52;p=0.27)。
- PCI组5年心肌梗死发生率高于CABG组(8% vs 5%;HR 1.57,95%CI 1.04-2.36)。
- PCI组5年再次血运重建率高于CABG组(16% vs 8%;HR 2.02,95%CI 1.46-2.79)。
- 两组5年死亡(7% vs 7%;HR 0.99,95%CI 0.67-1.46)和卒中(2% vs 3%;HR 0.65,95%CI 0.33-1.28)发生率无显著差异。
- 作者认为这些结果可为医患共同决策提供当代证据。
适用人群与场景
- 年龄≥21岁、不累及左主干的三支血管病变患者,且无心源性休克、无近期ST段抬高型心肌梗死、无严重左心室功能障碍、无既往CABG。
- 场景为欧洲、美国、加拿大、澳大利亚和亚洲的48家医院。
研究设计与关键结果
- FAME 3为多中心、开放标签、随机试验,纳入1500例患者,随机分配至FFR指导的PCI(使用当代佐他莫司洗脱支架)组757例或CABG组743例。
- 5年随访完成率:PCI组724例(96%),CABG组696例(94%)。
- 主要终点(5年死亡、卒中或心肌梗死复合终点)在PCI组119例(16%),CABG组101例(14%);HR 1.16(95%CI 0.89-1.52),p=0.27,无显著差异。
- 5年死亡:PCI组53例(7%),CABG组51例(7%);HR 0.99(95%CI 0.67-1.46)。
- 5年卒中:PCI组14例(2%),CABG组21例(3%);HR 0.65(95%CI 0.33-1.28)。
- 5年心肌梗死:PCI组60例(8%),CABG组38例(5%);HR 1.57(95%CI 1.04-2.36)。
- 5年再次血运重建:PCI组112例(16%),CABG组55例(8%);HR 2.02(95%CI 1.46-2.79)。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机试验的最终预设分析。
- 资助:Medtronic和Abbott Vascular。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于不累及左主干的三支血管病变且无心源性休克、无近期ST段抬高型心肌梗死、无严重左心室功能障碍、无既往CABG的患者,FFR指导的PCI与CABG在5年死亡、卒中或心肌梗死复合终点无显著差异,但PCI组心肌梗死和再次血运重建更高。
- 作者认为这些结果可为医患共同决策提供当代证据。
指南或共识出处
- FAME 3试验,ClinicalTrials.gov注册号NCT02100722。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Long-term outcomes following percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) might be changing because of improved techniques and better medical therapy. This final prespecified analysis of the Fractional Flow Reserve (FFR) versus Angiography for Multivessel Evaluation (FAME) 3 trial aimed to reassess their comparative effectiveness at 5 years.
METHODS: FAME 3 was a multicentre, randomised trial comparing FFR-guided PCI using current-generation zotarolimus-eluting stents versus CABG in patients with three-vessel coronary artery disease not involving the left main coronary artery. 48 hospitals in Europe, USA and Canada, Australia, and Asia participated in the trial. Patients (aged ≥21 years with no cardiogenic shock, no recent ST segment elevation myocardial infarction, no severe left ventricular dysfunction, and no previous CABG) were randomly assigned to either PCI or CABG using a web-based system. At 1 year, FFR-guided PCI did not meet the prespecified threshold for non-inferiority for the outcome of death, stroke, myocardial infarction, or repeat revascularisation versus CABG. The primary endpoint for this intention-to-treat analysis was the 5-year incidence of the prespecified composite outcome of death, stroke, or myocardial infarction. The trial was registered at ClinicalTrials.gov, NCT02100722, and is completed; this is the final report.
FINDINGS: Between Aug 25, 2014 and Nov 28, 2019, 757 of 1500 participants were assigned to PCI and 743 to CABG. 5-year follow-up was achieved in 724 (96%) patients assigned to PCI and 696 (94%) assigned to CABG. At 5 years, there was no significant difference in the composite of death, stroke, or myocardial infarction between the two groups, with 119 (16%) events in the PCI group and 101 (14%) in the CABG group (hazard ratio 1·16 [95% CI 0·89-1·52]; p=0·27). There were no differences in the rates of death (53 [7%] vs 51 [7%]; 0·99 [0·67-1·46]) or stroke (14 [2%] vs 21 [3%], 0·65 [0·33-1·28]), but myocardial infarction was higher in the PCI group than in the CABG group (60 [8%] vs 38 [5%], 1·57 [1·04-2·36]), as was repeat revascularisation (112 [16%] vs 55 [8%], 2·02 [1·46-2·79]).
INTERPRETATION: At the 5-year follow-up, there was no significant difference in a composite outcome of death, stroke, or myocardial infarction after FFR-guided PCI versus CABG, although myocardial infarction and repeat revascularisation were higher with PCI. These results provide contemporary evidence to allow improved shared decision making between physicians and patients.
FUNDING: Medtronic and Abbott Vascular.
参考来源
- Fearon WF, Zimmermann FM, Ding VY, et al. Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial. Lancet. 2025. PMID: 40174598. doi:10.1016/S0140-6736(25)00505-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。